Category: Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT)
-
Rybelsus Deep Vein Thrombosis Case Report: Medical Journal, 2026
Rybelsus (Semaglutide) Associated With Significantly Increased Risk Of Blood Clots (Posted by Tom Lamb at Drug Injury Watch) In this post, we point out a recent medical journal article that discusses a Rybelsus deep vein thrombosis case…
-
Wegovy, Rybelsus, and Ozempic Blood Clots Cases Are Not Part of Federal Court MDL at This Time
Semaglutide-related Side Effects Include Ischemic Stroke, Pulmonary Embolism, and Deep Vein Thrombosis (Posted by Tom Lamb at Drug Injury Watch) UPDATE: Cases involving blood clot-related injuries such as deep vein thrombosis or pulmonary embolism with the…
-
“New” Blood Clots Side Effect of Semaglutide Weight Loss Drugs Like Ozempic: Deep Vein Thrombosis
Research Finding: Semaglutide Increased the Risk of Deep Vein Thrombosis (DVT) by 266% in Patients with Type 2 Diabetes (Posted by Tom Lamb at Drug Injury Watch) UPDATE No Warnings About Blood Clots From Ozempic,…
-
JAK Inhibitors Safety Review by European Drug Regulator EMA Announced in February 2022
Xeljanz, Rinvoq, and Olumiant as Treatments for Inflammatory Disorders Have Been Under Scrutiny by FDA in the US (Posted by Tom Lamb at Drug Injury Watch) In December 2021 there was a notable JAK inhibitors…
-
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular Events
January 2022 Medical Journal Article Presents Full Set of Findings for the Xeljanz "ORAL Surveillance" Trial Which Started in 2014 (Posted by Tom Lamb at Drug Injury Watch) One year ago Pfizer released some preliminary…
-
December 2021 JAK Inhibitors Drug Class Label Changes: More Warnings and Use Restrictions
Risks of Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq (Posted by Tom Lamb at Drug Injury Watch) As background, in September 2021 the FDA announced that it was requiring…